Eribulin Effectiveness and Safety in Metastatic Triple-Negative Breast Cancer: A Narrative Review
Abstract
Triple-negative breast cancer is an aggressive and poor prognosis subtype of breast cancer. Eribulin has shown promise in the treatment of metastatic triple-negative breast cancer (mTNBC). This review aimed to provide a specific description, evidence, and discussion of the efficacy and safety of eribulin both as monotherapy and in combination with another agent in patients with mTNBC. The search was conducted in five databases (PubMed, ScienceDirect, Plos One, Wiley Online Library, and Cochrane Library) towards published articles during the 2013-2023 period. A total of 237 articles were identified. After removing 69 duplicates, 168 articles underwent the screening process and 10 articles met the research criteria. Eribulin monotherapy effectiveness profile includes: overall survival (10.8-17.6 months), progression-free survival (2.8-3.2 months), partial response (21.0%-58.7%), progressive disease (15.5% -47.0%), and stable disease (28.8%-32%). However, there were no cases of complete response. Combination of eribulin with other agents' effectiveness profiles includes: overall survival (8.3-14.5 months), PFS (2.6-8.1 months), partial response (31.8-76.0%), complete response (2.4-8%), progressive disease (8.0-28%), and stable disease (8.0-52.3%). Eribulin monotherapy's safety profile is similar to that of combination therapy. No grade 5 adverse event was reported during monotherapy or in combination with other agents. The grade 4 adverse events reported are neutropenia, leukopenia, thrombocytopenia, anemia, peripheral neuropathy, fatigue, diarrhea, vomiting, dyspnea, back pain, arthralgia, febrile neutropenia, dyspnea, constipation, general physical health deterioration, alopecia. the all-grade adverse events with a percentage above 50% are neutropenia, leukopenia, thrombocytopenia, asthenia, alopecia, elevated AST, elevated ALT, hand-foot syndrome, fatigue, anemia, peripheral neuropathy, oral mucositis, and nausea.
Full text article
References
Authors
Copyright (c) 2025 Herleeyana Meriyani, Dwi Arymbhi Sanjaya, Rr. Asih Juanita, Nyoman Budiartha Siada, Nurul Chusna
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors continue to retain the copyright to the article if the article is published in the Borneo Journal of Pharmacy. They will also retain the publishing rights to the article without any restrictions.
Authors who publish in this journal agree to the following terms:
- Any article on the copyright is retained by the author(s).
- The author grants the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share work with an acknowledgment of the work authors and initial publications in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of published articles (e.g., post-institutional repository) or publish them in a book, with acknowledgment of their initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their websites) prior to and during the submission process. This can lead to productive exchanges and earlier and greater citations of published work.
- The article and any associated published material are distributed under the Creative Commons Attribution-ShareAlike 4.0 International License.
Article Details
